ZYMEDI has a platform that fuels continuous innovation

HOMEOS logo

Our in-house drug discovery platform is named HOMEOS, after ARSs’ capability of maintaining homeostasis. Also known as AIDD (aminoacyl-tRNA synthetase [ARS]-focused integrated drug development platform), it allows us to maintain a nonexhaustive pipeline of first-in-class drugs by exploring the plethora of ARS biology.

ARSs are associated with angiogenesis, inflammation, tumorigenesis, and other important pathophysiologic processes in human diseases. By targeting these pathways and their respective imbalances, we can help restore the body to balance.

HOMEOS logo

We maintain a comprehensive proprietary database for all information related to ARS:

DARSOME database

DARSOME: disease-associated ARS genome and proteome. In-depth analysis of proprietary disease-associated ARS variations (genome, proteome, and secretome database).

INTER ARS database

INTER-ARS: propriety ARS interactome database.

INTEGRA database

INTEGRA: integrated efficacy assay platform. The design of the disease-mimicking integrated drug-screening system.

MOST database

MOST: multimodality lead discovery platform. Discovery of ARS-focused hits and leads (chemical, antibody, peptide, biologics).

AILO database

AILO: AI-based lead optimization platform. Lead optimization for druggable candidates. First-in-class drug.

Our pipeline includes a first-in-class monoclonal antibody for pulmonary arterial hypertension (PAH) that targets membrane-exposed Lysyl-tRNA synthetase (KARS1).
ZYMEDI is developing a first-in-class small molecule compound that inhibits multifaceted, proinflammatory activities of KARS1.
Our pipeline has a pan-KRAS inhibitor targeting AIMP2-DX2 for KRAS-mutated cancers.

Contact ZYMEDI

We welcome joint ventures, strategic investors, and in-licensing partners who want to be part of our mission to identify novel therapeutics for hard-to-treat disease areas. To learn more, or to partner with ZYMEDI, contact us today.